BETHESDA, Md., April 13, 2021 /PRNewswire/ — Noura Abul-Husn, MD, PhD, FACMG is the recipient of the ACMG Basis for Genetic and Genomic Medication’s 2021 Dr. Michael S. Watson Genetic and Genomic Medication Innovation Award—the “Watson Award”—named for the American Faculty of Medical Genetics and Genomics first and longstanding government director, Dr. Michael Watson, FACMG.
“I’m actually honored and delighted to obtain this award from the ACMG Basis,” mentioned Dr. Abul-Husn. “I’m deeply dedicated to rising an progressive program that interprets genomic findings into improved affected person take care of numerous populations.”
“We’re delighted to announce that Dr. Noura Abul-Husn is the 2021 recipient of the Dr. Michael S. Watson Genetic and Genomic Medication Innovation Award,” mentioned Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Basis. “Dr. Abul-Husn has been a pioneer within the utility of genomics to enhance well being in numerous populations, serving to to pave the way in which in direction of equitable entry to genomic drugs for all folks.”
Noura S. Abul-Husn, MD, PhD is an affiliate professor of Medication and Genetics, founding chief of the Division of Genomic Medication within the Division of Medication, and scientific director of the Institute for Genomic Well being on the Icahn College of Medication at Mount Sinai. She is board licensed in Inner Medication and Medical Genetics and is a fellow of the American Faculty of Medical Genetics and Genomics.
Dr. Abul-Husn is a physician-scientist whose analysis focus is to uncover the scientific influence of human genetic variation in numerous and unselected populations. Her scientific contributions embrace pioneering genome-first approaches in population-based biobanks to offer new scientific insights and inform genome-guided therapeutic discovery. She is an skilled at leveraging large-scale genomic knowledge linked to digital well being data, and her work has been revealed in main journals, together with Science, Cell, and the New England Journal of Medication. Dr. Abul-Husn’s translational analysis and scientific targets are to combine modern genomic purposes into routine scientific care and drive the equitable implementation of genomic drugs. She just lately launched a genomic screening program for medically actionable situations tailor-made to ancestrally numerous members of the BioMe Biobank in New York Metropolis. She is a principal investigator within the eMERGE (digital Medical Information and Genomics) Community, which goals to combine polygenic danger data into the care of numerous affected person populations. Dr. Abul-Husn directs a Genomic Well being Clinic to offer the scientific infrastructure for genomic danger communication, and has initiated a Genomic Medication Observe for Inner Medication residents to increase genomics information throughout medical specialties.
Dr. Abul-Husn has a BSc Honors in Life Sciences and MSc in Pharmacology from Queen’s College in Canada. She accomplished her MD and PhD on the Icahn College of Medication at Mount Sinai Medical Scientist Coaching Program in New York. She acquired the Terry Ann Krulwich Doctoral Dissertation Award for having the highest thesis and was elected to the Alpha Omega Alpha Medical Honor Society. She went on to finish residency in Inner Medication and Medical Genetics at Mount Sinai, and was Chief Resident in Medical Genetics. Dr. Abul-Husn has senior-level pharmaceutical trade expertise, having served as director of Translational Genetics on the Regeneron Genetics Heart, throughout which period she was acknowledged by a 2017 Westchester’s 40 below 40 Rising Star Award.
The Watson Award acknowledges those that have demonstrated innovation of their work and developed or carried out a brand new idea, methodology or concept that has had vital influence on genetic and genomic drugs. The award was created to honor the position Dr. Watson performed throughout his almost 20 years on the helm of ACMG whereas the sector of genetic and genomic drugs emerged and advanced into the far-reaching observe it’s immediately, a interval throughout which Dr. Watson helped ACMG assume its place on the forefront of coverage and guideline improvement.
“Dr. Noura Abul-Husn is the right recipient for the Dr. Michael S. Watson Genetic and Genomic Medication Innovation Award,” mentioned Max Muenke, MD, FACMG, CEO of the ACMG. “Dr. Abul-Husn’s training as an MD, PhD, her coaching as an internist – medical geneticist, and her observe report of labor revealed in high-profile journals, make her one of the influential colleagues to translate genomic drugs into optimum affected person care. I’m personally delighted that Dr. Abul-Husn’s work features a give attention to the care of people from numerous populations.”
In regards to the ACMG Basis for Genetic and Genomic Medication
The ACMG Basis for Genetic and Genomic Medication, a 501(c)(3) nonprofit group, is a neighborhood of supporters and contributors who perceive the significance of medical genetics and genomics in healthcare. Established in 1992, the ACMG Basis helps the American Faculty of Medical Genetics and Genomics (ACMG) mission to “translate genes into well being.” By way of its work, the ACMG Basis fosters charitable giving, promotes coaching alternatives to draw future medical geneticists and genetic counselors to the sector, shares details about medical genetics and genomics, and sponsors essential analysis. To study extra and assist the ACMG Basis mission to create “Higher Well being by way of Genetics” go to www.acmgfoundation.org.
Kathy Moran, MBA
[email protected]
SOURCE American Faculty of Medical Genetics and Genomics